Medtronic issues statement on the fda circulatory systems devices advisory panel vote for the symplicity spyral renal denervation system

Dublin , aug. 23, 2023 /prnewswire/ -- today, medtronic announced the outcome of the u.s. food & drug administration (fda) circulatory system devices panel (csdp) meeting to review data presented in support of the medtronic symplicity spyral™ renal denervation (rdn) system. the panel committee voted unanimously (13-0) on safety and in favor (7-6) of the effectiveness of the symplicity blood pressure procedure.
MDT Ratings Summary
MDT Quant Ranking